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Early interventions for youths at high risk for bipolar disorder: A 
developmental approach 
Abstract 
In recent decades, ongoing research programs on primary prevention and early identification 
of bipolar disorder (BD) have been developed. The aim of this article is to review the 
principal forms of evidence that support preventive interventions for BD in children and 
adolescents and the main challenges associated with these programs. We performed a 
literature review of the main computerised databases (MEDLINE, PUBMED) and a manual 
search of the literature relevant to prospective and retrospective studies of prodromal 
symptoms, premorbid stages, risk factors, and early intervention programs for BD. Genetic 
and environmental risk factors of BD were identified. Most of the algorithms used to measure 
the risk of developing BD and the early interventions programs focused on the familial risk. 
The prodromal signs varied greatly and were age-dependent. During adolescence, depressive 
episodes associated with genetic or environmental risk factors predicted the onset of 
hypomanic/manic episodes over subsequent years. In prepubertal children, the lack of 
specificity of clinical markers and difficulties in mood assessment were seen as impeding 
preventive interventions at these ages. Despite encouraging results, biomarkers have not thus 
far been sufficiently validated in youth samples to serve as screening tools for prevention. 
Additional longitudinal studies in youths at high risk of developing BD should include 
repeated measures of putative biomarkers. Staging models have been developed as an 
integrative approach to specify the individual level of risk based on clinical (e.g., prodromal 
symptoms and familial history of BD) and non-clinical (e.g., biomarkers and neuroimaging) 
data. However, there is still a lack of empirically validated studies that measure the benefits 
of using these models to design preventive intervention programs.  
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Introduction 
Over the past few decades, preventive interventions have been proposed to prevent or limit 
the consequences of bipolar disorder (BD) in adults. Because more than half of adult patients 
with BD present their first episode before the age of 18 [1,2], these programs would mainly 
concern children and adolescents. This concern is of particular importance with regard to the 
high level of functional impairment in affected children and adolescents. BD is the fourth 
leading cause of disability among youths aged 10-24 worldwide and is associated with an 
increased risk of suicide [3,4]. In this paper, the evidence that supports the development of 
such interventions at these ages is discussed. First, to understand the growing interest in the 
development of a preventive approach, the natural course of BD is discussed. Second, we 
examine whether the following criteria for the development of an effective prevention of BD 
in paediatric samples have been met: (i) genetic and environmental risk factors for BD must 
be identified in view of defining a target population; (ii) clinical markers that predict the 
onset and/or the course of the disease must be determined; (iii) endophenotypes or 
biomarkers that reflect an early pathological process could help to identify individuals who 
require special attention, and (iv) the effectiveness of preventive interventions must be 
evaluated. Finally, the use of staging models that were previously developed for psychosis, 
has been proposed for BD. These models were conceived as tools based on clinical (e.g., 
symptoms and family history of BD) and non-clinical (e.g., neuroimaging and biological 
markers) parameters for measuring the risk of progression over the course of the disease. It is 
  4 
seen as a rational approach to adapting treatments with potential side-effects to a specific 
situation according to the individual level of risk. However, despite a theoretical framework 
that supports the use of staging models in BD, few studies have examined the empirical 
evidence. This review will examine the internal and external validity of models that focus on 
the transition from a non-symptomatic at-risk status to the first manic episode.  
 
1. The life-time course of bipolar disorder 
 
Although BD has traditionally been described as a cyclical disorder with euthymic periods, in 
recent decades, the clinical importance of inter-episode symptoms has been highlighted. It 
has been noted that symptom-free periods are actually rare in bipolar patients, who continue 
to report subsyndromal affective symptoms between episodes [5]. An aggravation of the 
disease with more severe symptoms and shorter periods between relapse is observed 
throughout the course of BD in a sizeable proportion of patients [6-9]. The concepts of 
kindling and neuro sensitisation were coined to describe the phenomenon of a progressive 
increase in episode frequencies as the mood episodes repeated [8,9]. Although this concept 
have largely been cited in support of the promotion of early interventions in BD, this 
assumption has been contradicted by empirical evidences [10,11]. In a 30 year follow-up 
study among outpatients with BD (N=220), Angst and Selloro found that a shortening of 
cycle length only occurred in the first few, but not in later episodes [10]. In addition to 
subthreshold symptoms, some degree of cognitive impairment also persists during euthymic 
periods in patients with BD [12-14]. Increasing cognitive difficulties have been reported over 
the course of the disorder and are correlated with the number of manic episodes [15]. 
Longitudinal studies in adults have supported the assumption that inter-episode functioning 
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decreases as the disease progresses in most individuals with BD [16,17,6]. This progressive 
course is seen as a key factor in explaining the poorer functional outcomes in BD patients 
with delayed treatment compared with others [1,2,18]. Indeed, patients with a prolonged 
phase of untreated illness report on average a lower rate of employment [19], a higher 
number of hospitalisations [20], more forensic complications, and a higher level of functional 
impairment [3,21]. The view of BD as both a progressive and cyclical disease is also 
supported by different responses to treatment observed according to the stages of the illness 
[6,9,18]. The number of manic episodes that a patient experiences has been associated with 
greater resistance to pharmacological treatment [8,9,22]. However, these findings were not 
replicated when the response to lithium was examined in a large 20-year follow-up study 
among adults with BD [23]. Concerning psychological interventions, cognitive behavioural 
therapy (CBT) and psychoeducational therapy have shown more effectiveness in the early 
stages of the disease compared with the later stages [24-26]. However, a meta-analysis found 
that the number of previous thymic episodes had no impact on psychotherapeutic 
effectiveness [27]. These conflicting results could stem from the heterogeneity of BD in 
terms of the illness course and treatment response [28,29]. Preventive interventions would 
aim to reverse or slow the life-time course of BD, in particular in those who present severe 
disease progression. In the next section, the criteria that are required for the development of 
such programs for BD in children and adolescents will be examined. 
 
2. Criteria for the development of effective preventive interventions in the 
paediatric population 
 
(i) Genetic and environmental risk factors 
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If a preventive strategy is to be developed, genetic and non-genetic risk factors must be 
determined to identify sub-groups that are at high risk of BD transition. Table 1 presents the 
main risk factors that have been identified for the onset and progression of BD. 
 
Genetic factors 
A positive family history of BD is the strongest independent risk factor for the development 
of related mood disorders [30,31]. Twin and family studies have reported a 59-87% 
heritability of BD, and the concordance rates between identical twins range from 40 to 97% 
[32]. Based on the DSM-IV criteria for BD-I and BD-II, first-degree relatives have a 23% 
chance of developing a mood disorder; within this 23%, the chance of developing a form of 
BD is approximately 9% [30]. Considering the high heritability rate, the offspring of BD 
parents appear to be good candidates for determining the efficacy of early intervention 
strategies. However, it should be mentioned that such an approach would omit subjects who 
do not have first-degree relatives with BD.  
 
Environmental factors 
In addition to genetic predisposition, some environmental risk factors could impact the life-
time course of BD. Approximately 50% of BD patients have histories of severe trauma or 
abuse during childhood [33]. In retrospective studies and prospective outpatient studies, early 
sexual abuse has been associated with an earlier age of BD onset, a greater frequency of 
comorbidities, increased symptom severity and suicidal ideation, an increased number of 
mood episodes, and greater treatment resistance [33-35]. For example, Geller et al. found that 
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low ratings of maternal warmth and greater parent-child conflict are associated with earlier 
recurrences over four years among childhood and preadolescent bipolar patients [33]. The 
poorer course of bipolar youths who were exposed to childhood abuse/neglect has also been 
supported by epidemiological studies. Data from the National Comorbidity Survey 
Replication indicated that a history of maltreatment predicted earlier onset and longer episode 
duration of BP [34]. The dose-effect relationship observed between childhood maltreatment 
and the severity of BD suggests that adverse life events have an effect across the different 
stages of the disease [35]. It has been suggested that early adversity mediates the relationship 
between genetic vulnerability and an early onset of the illness, which in turn predicts a less 
favourable prognosis [33]. Two general comments are worth mentioning with regard to these 
findings. On one hand, the association between abuse/neglect and the onset of BD was not 
investigated in the prospective high-risk studies conducted in the offspring of parents with 
BD. Thus, regarding maltreatment as a strong prognosis factor does not imply that it should 
be considered as an independent risk factor for the onset of BD. Moreover the fact that high 
conversion rates to BD were observed in pediatric sample associated with a low prevalence of 
abuse and neglect indicates that stressful life events are neither necessary nor sufficient to 
develop BD [35,36]. The association between BD and maltreatment found in cross-sectional 
studies of the offspring of parents with BD could partly reflect general difficulties in the 
parenting practices of adults with BD [36]. On the other hand, it is important to determine 
whether the results found in outpatient studies were an artefact of the inclusion of youths with 
dysregulated mood who were misdiagnosed as having BD (such as youths with Disruptive 
Mood Dysregulation Disorder).  
Substance use also impacts the course of BD. Approximately, 60% of individuals with BD 
will develop substance abuse or dependence [37]. Conversely, substance abuse was reported 
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to be a risk factor for developing BD in retrospective studies and in prospective studies 
among the offspring of parents with BD [38,39]. 
Long-term treatment with antidepressant medications precipitates or exacerbates manic 
symptoms and reduces the age of onset of mania [40]. A potential risk for episodes of mania 
induced by stimulant medications was supported by preliminary evidence; but not confirmed 
by more recent prospective studies [41,42].  
 
[Insert Table 1 about here] 
 
Limitations and further research 
Beyond the recognition of environmental and genetic risk factors for BD in children and 
adolescents, there is still much to be done to understand the interactions between these 
factors. Some of the identified factors could be inter-correlated (e.g., substance abuse and 
maltreatment), some factors could be necessary for the development of others, and some 
factors could simply co-occur. A better understanding of the common pathophysiological 
pathways that mediate the effect of different risk factors could help to develop effective 
interventions. For example, Meyer et al. found that the effect of maternal negativity on the 
early onset of BD among the offspring of mothers with BD was mainly mediated by 
difficulties in executive cognitive abilities [43]. Finally, the moderating effects of protective 
factors, such as temperament and social and familial environment, should be better 
understood.  
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(ii) Specific clinical symptoms during the prodromal stages 
 
Before detailing prodromal symptoms, several points about methodologic issues are worth 
noting. Different types of studies have been conducted to determine which symptoms precede 
the onset of BD. Retrospective studies are surveys in which adult participants describe the 
symptoms that precede the onset of BD [1,44-46,2]. These retrospective studies have 
supported the view that a prodromal phase exists in BD during childhood [1,2]. However, 
methodological biases (such as a recall bias or a lack of precision in estimating the age of 
onset) make modelling the course of the prodromal symptoms difficult. In contrast, 
prospective studies provide reliable and detailed data on the course of bipolar prodromal 
symptoms because clinical symptoms are estimated through repeated assessments of youths 
prior to the onset of BD. Recent reviews have detailed the prodromal symptoms of BD 
[47,18]. In this article, we present only the main results from those prospective studies. 
 
Studies of child and adolescent outpatients 
Follow-up studies that monitored the rates of diagnostic conversion to BD among outpatient 
youths with behavioural/emotional problems have been conducted. Typically, subjects are 
included when their symptoms are severe enough for them or their families to seek admission 
for assessment and treatment. Consequently, these studies are prone to Berkson bias and a 
high comorbidity rate is usually reported. The Course and Outcome of Bipolar Youth 
(COBY) study is a large US prospective outpatient study that included youths with manic 
symptoms who did not meet the criteria for a diagnosis of maniac/mixed episode (i.e., bipolar 
disorder not otherwise specified, BD-NOS). The COBY team found that 25% of 92 children 
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and adolescents with BD-NOS had converted to BD-I or BD-II at a 2-year follow-up [48]. At 
a 4-year follow-up, 38% of 141 BD-NOS subjects had converted to BD-I or BD-II.  
Geller et al. examined the transition to BD among young adults who had participated in a 
study of pharmacological treatment for childhood depression. At a 10-year follow-up, 49% of 
72 subjects with prepubertal major depression had converted to some form of BD [49]. 
Kochman et al. conducted a 2-year follow-up study in children and adolescents with a major 
depressive disorder and probands with bipolar disorder. They found that those who presented 
a combination of elevated mood with irritability and rapid mood fluctuations (labelled 
cyclotaxia) were more likely to develop a manic episode [50].  
Akiskal et al. found that “mood lability”, “energy–activity” and “daydreaming” trait factors 
strongly predicted conversion to BD-II in youths with unipolar depression [51]. 
 
Studies in a community-based sample 
Longitudinal studies conducted in an unselected community-based sample can facilitate the 
generalisation of findings. In the Dunedin (New-Zealand) birth cohort (N=922 children), 
Kim-Cohen et al. found that 74% of the adults with BD presented early signs before 18 and 
50% before 15 years. All of the adults who developed BD had already presented a paediatric 
psychiatric disorder: anxiety disorder, and/or depressive disorder, and/or disruptive disorder 
[52]. In The Great Smoky Mountains Study (N=717 children), youths who developed BD 
were more likely to present a psychiatric disorder in adolescence, such as anxiety (OR=20), 
depressive disorder (OR=5.4), disruptive disorder (OR=6.3) and personality disorder 
(OR=6.8) [53,54]. In a 15-year follow-up Swedish community-based study (N=2,300), 
Paaren et al. reported that among adolescents with a major depressive disorder, those with 
early disruptive disorders or multiple somatic symptoms in childhood were more likely to 
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develop BD in adulthood (respectively, OR=3.6 and OR=6.6) [55]. In this study, of the 64 
adolescents with hypomania spectrum episodes during childhood, only 6 developed a 
hypomanic/manic episode as adults. Anxiety disorders (panic attack and general anxiety 
disorder) substantially increase this risk (OR=12.0) [55]. 
 
Studies of offspring of parents with BD 
As developed earlier, heritability is the most robust risk factor for BD. Therefore, providing 
data about bipolar prodrome by studying the offspring of probands with BD is a major 
strategy. In addition to the cost of these studies, the main limitation concerns the 
generalisation of the findings to youths who do not have a family history of BD. 
Akiskal et al. conducted a 3-year follow-up study on youths who were admitted for services 
and whose parents presented BD. Those who developed BD were more likely to present 
anxiety, minor mood symptoms and adjustment disorders before the onset of BD [56]. The 
first mood disturbances were depressive in polarity and occurred before adolescence, whereas 
mixed and psychotic episodes occurred after puberty. 
Hillegers et al. studied the risk of developing BD in a sample of 129 high-risk Dutch 
adolescents [35]. After 5 years of follow-up, 12 out of the 13 adolescents who developed BD 
had first presented a depressive episode at adolescence. On average, a hypomanic episode 
appears 4.9 years after the first depressive episode.  
Shaw et al. compared 110 at-risk children who had a BD-I parent to children who had healthy 
parents in the Amish population. They found a higher frequency of broad spectrum episodic 
symptoms in offspring of bipolar parents: anxiety, inattention at school, easily excited 
behaviour, hyper alertness, mood lability, and somatic complaints [57]. A further 5-year 
follow-up led to determining five additional symptoms in adolescents: variations in sleep and 
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energy, problems with thinking/concentration, excessive talking, and loud talking [58]. 
Egeland et al. suggested that the prodromal symptoms of BD would encompass episodic 
signs before 6 years old (such as crying, anxiety, over sensitivity, somatic complaints) and 
more adult-like symptoms from 7 to 12 (such as anxiety and variation in sleep and energy, 
emotional lability, shyness, functional impairment) [58]. 
Duffy et al. assessed the diagnostic status and conversions to BD after a 4-year follow-up of 
127 high-risk offspring [36]. The lifetime prevalence of BD increased from 6% to 20% 
compared to the offspring from control families. Of 40 offspring with sleep and/or anxiety 
disorders, 12 developed BD, and 12 developed depressive disorders. The index mood episode 
in those who developed BD was almost always depression. A history of anxiety was found to 
increase the risk for the development of any mood disorder from 40% to 85%, approximately 
8 years after the beginning of the anxiety symptoms [40]. Similarly, sleep disturbances that 
preceded BD occurred several years before the onset of the first mood episode. The same 
team hypothesised that a majority of offspring of bipolar adults who went on to develop BD 
observed a typical chronological sequence of prodromal symptoms. Among the 207 
offspring, approximately 71% of the children who developed BD followed this sequence: 
non-mood symptoms (i.e., sleep disturbances and anxiety disorder) first appear in the 
prepubertal child; then, non-specific minor mood symptoms emerge around puberty; the 
onset of recurrent major depressive episodes occurs later in mid-adolescence; and finally, the 
first hypomanic/manic episode occurs years later [39].  
Axelson et al. examined the risk of developing BD in 391 high-risk offspring aged 6-18 
years. After a 6.8-year follow-up, subthreshold manic or hypomanic episodes (OR=2.3), 
major depressive episodes (OR=2.0), and disruptive behaviour disorders (OR=2.1) were 
associated with a higher risk of developing BD [59]. 
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Limitations and further research 
Based on previous findings, a model has been proposed (Figure 1) to illustrate the course of 
prodromal symptoms over time in children and adolescents before the onset of BD in young 
adults. This model highlights the increasing specificity of the prodromal symptoms observed 
over time and their different predictive values, depending on the stage of development. Two 
different periods should be distinguished. In prepubertal at-risk children, non-mood (e.g., 
anxiety) and minor mood (e.g., sleep disturbance) symptoms were associated with a higher 
transition to BD. Identifying the possible candidates for bipolar preventive intervention based 
on these symptoms raised two difficulties. First, on a practical level, concerns have been 
raised regarding the difficulties of distinguishing minor mood symptoms from mood 
variations within the normal range in the youngest children [60,61]. Second, it is still unclear 
to what extent these symptoms predict BD, or any other psychiatric disorder (e.g., unipolar 
depression or psychosis). As suggested by Kim-Cohen et al., bipolar prodromal symptoms 
are difficult to distinguish from symptoms that precede unipolar depression or psychosis [52]. 
In addition, the inclusion of paediatric subthreshold manic-like symptoms into the adult 
bipolar spectrum raised a great deal of controversy [60]. With respect to this issue, the 
substantial amount of literature that was devoted to the so-called paediatric presentation of 
BD clarified some issues. Evidence supports that episodic and persistent mood symptoms 
should be distinguished because only the former predicts BD [62-64]. For example, Stringaris 
et al. noted that among 84 youths with non-episodic irritability, only one developed 
hypomanic/manic or mixed episodes over a 2-year follow-up [62]. Similarly, a large amount 
of longitudinal data supports that persistent and chronic mood symptoms predict unipolar 
depression and anxiety, but not BD, in adults. Such distinctions have been endorsed by the 
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recent inclusion of Disruptive Mood Dysregulation in the chapter of depressive disorders in 
the DSM-5 classificatory systems. 
In adolescents, high-risk studies showed that in most cases, affective disturbances begin 
during adolescence and are depressive in polarity [36,35,57]. Few manic or mixed episodes 
were reported before puberty, while more than 90% of BD patients presented depressive 
symptoms in mid-adolescence [65,35]. Certain characteristics of the depressive episode were 
associated with an increased risk of developing BD: an acute onset [66], a weight gain, 
somatic preoccupations, a diminished concentration, a predominantly irritable mood [67], 
psychotic features, severe psychomotor retardation (e.g., Cotard syndrome) [68], and 
medication-induced hypomanic symptoms [69].  
  
[Insert Figure I about here] 
 
Research on at-risk children for BD highlight two fundamental principles of developmental 
psychopathology: equifinality and multifinality. Equifinality means that multiple 
developmental pathways can converge on the same clinical outcome [70]. A large amount of 
evidence in adults supports that different subtypes of BD with distinct risk factors and clinical 
courses exist. Such heterogeneity could represent additional difficulty in determining a 
unique pattern of bipolar prodromal symptoms for all presentations [29,28]. The notion of 
multifinality reflects the variety of trajectories that could arise from one specific constellation 
of prodromal symptoms. On the one hand, the lack of specificity of prodromal bipolar 
symptoms makes the identification of a clear at-risk group based on clinical approach 
difficult, especially because subthreshold manic and depressive symptoms are much more 
common in the general population than those for psychosis. On the other hand, a large 
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overlap between prodromal symptoms for psychosis and for BD have been observed [71]. At 
this time, preventive programs should focus on the identification of depressive episodes in 
youths who present with genetic and/or environmental risk factors. Such programs must be 
considered as a secondary prevention because these symptoms reflect the initial thymic 
episode as illustrated in Figure I. 
 
 
(iii) Endophenotypes and biomarkers  
 
Considering the limited specificity of symptoms that are described during the prodromal 
stages, non-clinical indicators could prove to be valuable in distinguishing youths who are at 
high risk of developing BD from others. An endophenotype is a heritable biological trait that 
serves as a marker of risk for a later disorder [72]. Endophenotypes could help to identify 
individuals who are likely to manifest prodromal states of BD. Biomarkers have been 
proposed to reflect dysfunctional neurobiological mechanisms that facilitate the onset and 
progression of BD [73]. Moreover, the identification of such markers could help to define 
possible targets for preventive approaches. 
Temperamental traits 
Studies have examined whether specific temperamental traits can confer additional risk of 
developing BD in vulnerable individuals [74,75,50,76-78]. Most of these studies have 
compared temperamental features between offsprings of unaffected parents, offspring of 
bipolar parents with and without psychopathology [75,74,77]. For example, emotionality 
(defined as an easy tendency to cry and react intensively when upset) was positively 
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associated with the risk of having a mood disorder in a cohort of offsprings of parents with 
BD [75]. Doucette et al. [78] examining temperament profiles among offspring of a parent 
with BD (N=221) found that those who exhibited a high level of emotionality were more 
likely to develop a mood disorder (OR=1.24) compared to offspring from families with 
unaffected parent. 
A cyclothymic temperament (i.e., with highly mood-lability and emotionally overactive) was 
found to be a predictor of switching to BD in a population of children and adolescents with 
major depressive disorder (N=80) in a 2-year follow-up study [50]. Evans et al. [76] 
confirmed that cyclothymic temperamental traits are present at a higher rate within BD adults 
than in unaffected relatives of patients with BD, and then in controls. 
As noted by Duffy et al. [75], further longitudinal studies of temperament features that 
predispose to BD could help to a better understanding of the interplay between genetic 
factors, psychopathology and undesirable life events in youth who later develop BD. Further 
studies are also needed to determine how these temperament traits cosegregate with BD 
within families and if it is specific to BD [74]. 
 
Endocrine and inflammatory markers 
Preliminary studies in this field have explored the role of cortisol and the increased activity in 
the hypothalamic-pituitary-adrenal (HPA) axis in mood disorders [79]. Subtle abnormalities 
in the HPA system were found to predict the development of affective disorder. For example, 
high-risk offspring of parents with BD tend to exhibit higher levels of cortisol during the 
afternoon compared to low-risk offspring [79]. However, further studies are needed to 
understand whether cortisol can be considered a marker of vulnerability to BD, an 
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etiopathological factor, or the biological response to chronic stress in youths who present 
non-specific emotional/behavioural symptoms. A major focus was placed on markers of 
neuroinflammation, neurotrophic factors and oxidative stress, considering their putative roles 
in the pathophysiology of BD [6,73,80,14,81,82]. An increase in the level of peripheral pro-
inflammatory markers (such as TNF-α and interleukine-6) and a decrease in the level of 
circulating brain-derived neurotrophic factor (BDNF) were reported initially during thymic 
episodes and then during euthymic periods [83-85]. Despite the keen interest in the 
development of inflammatory markers for BD, caution is required because the main 
assumptions were extrapolated from studies that were conducted in adults with existing BD. 
For example, none of the studies of biomarkers in BD that were reviewed in a recent meta-
analysis included subjects who were below the age of 18 years [73]. Only two studies have 
been conducted with paediatric samples. Padmos et al. found that monocyte activation of 
inflammatory genes predicted the development of mood disorders in adolescent bipolar 
offspring (n=54) [86]. Mesman et al. conducted a prospective study to examine the evolution 
of inflammatory biomarkers in 140 children of parents with BD. They found an increased 
expression of genes that are involved in the inflammatory process during adolescence (e.g., 
cytokines pentraxin 3), and a decrease in the expression of BDNF [87].  
 
Neurocognitive impairment 
When it exists, the neurocognitive impairment that is found in BD usually appears at a late 
stage of the disease. For example, unlike psychosis disorders, such deficits were not 
systematically reported after the first acute episode [88]. However, minor deficits in 
executive function, verbal memory, and attention have been described in unaffected children 
who are at risk of developing the disease [88-91,43]. Deficits in the labelling of facial 
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emotional expression have been found in unaffected relatives compared to healthy control 
subjects [89]. Schenkel et al. found that bipolar youths had more difficulty performing social 
cognitive tasks that measure theory of mind (i.e., inferences of others’ thoughts or intentions) 
compared with controls, especially in emotional contexts [90]. Whitney et al. noted 
significant impairments in social reciprocity in youths who have a parent with BD and 
presented mood dysregulation symptoms without BD. However, in this study, no difference 
in performance with regard to theory of mind or affect recognition was found [91]. A smaller 
study on the offspring of BD parents reported an association between the results on the 
Wisconsin Card Sorting Test and a later risk for the development of BD [43].  
 
Neuroanatomical features 
Cortical atrophy, an enlargement of the ventricles and a reduction in the grey matter volume, 
were noted over the course of BD [14,92-94]. However, compared to psychosis disorders, 
fewer structural impairments were found at an early and very early stage (e.g., prior to the 
onset of the first thymic episode) [93]. A progressive loss of brain grey matter in the frontal 
lobe was reported in a 2-year follow-up period after the first psychotic episode relative to 
controls [95]. Emerging data from longitudinal neuroimaging studies are beginning to 
elucidate abnormalities in cortical development associated with a higher risk of developing 
BD. For example, a reduction in the level of N-acetylaspartate, a marker of neuronal 
integrity, was found in the dorsolateral prefrontal cortices and hippocampi of children who 
are at risk of developing BD [96]. Singh et al. reported atypical patterns of prefrontal and 
subcortical intrinsic connectivity in the healthy offspring of parents with BD [97]. 
Abnormalities in amygdala development and in other regions of the limbic system (e.g., the 
hypothalamic nuclei) in BD were also found in structural and functional neuro-imaging 
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studies [98,93]. It has been suggested that such neuroanatomical changes that occurred at a 
very early stage of BD could partly explain the increased vulnerability to environmental 
stress that is observed in at-risk youths [9,14,6,12].  
 
Limitations and further research 
In recent decades, studies on biological and neuroimaging biomarkers have led to a better 
understanding of the physiopathological mechanisms that are involved in BD. Moreover, the 
lack of specificity of current risk factors and prodromal clinical symptoms strongly supports 
the developing of biomarkers to identify youths who have a higher risk of developing BD. 
Ideally, biomarkers will help to measure the accurate risk of developing BD and guide 
treatment in youths with non-specific symptoms (e.g., for adolescents who are referred for a 
first episode of depression) [99]. Encouraging findings that concern the inflammatory 
biomarkers at a later stage of BD have been examined in adults, but few studies have been 
conducted in youths. Preliminary studies should be replicated in larger samples and should 
use a longitudinal design to test the predictive validity of such biomarkers. Because much 
focus is put on the sensitivity of putative biomarkers, too little attention is paid to their 
specificity. For example, Mesman et al. reported that the abnormal expressions of genes that 
are involved in inflammation did not differ between youths who have developed a mood 
disorder, those who have developed a non-mood disorder, and those who have not developed 
any psychiatric disorder [87]. In contrast, Padmos et al. noted that monocyte gene activation, 
which is found in adolescent bipolar offspring, might potentially predict the development of 
mood disorders [86]. Moreover, the identification of one biomarker as a predictor for both 
BD and other psychiatric disorders, such as psychosis disorders, could also reflect the overlap 
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between these diseases. Further studies would be needed to assess the extent to which 
biomarkers are specific to BD or reflect a general vulnerability to psychiatric disorders. 
 
(iv) Efficacy of preventive interventions 
 
The objectives of a preventive intervention are to reduce early symptoms, enhance the ability 
to cope with dependent and independent stressors, and prevent or delay the onset of a 
disorder [100]. Psychosocial and pharmacological treatments have been proposed as 
preventive interventions for youths who are at risk of BD. 
  
Psychosocial interventions 
The use of psychoeducational or psychotherapeutic interventions as a first step to preventing 
BD has been proposed, given the favourable benefit/risk ratio and the greater level of 
satisfaction among young patients and their families when compared to pharmacological 
treatment [101]. Four studies have been conducted to evaluate the efficacy of psychosocial 
interventions in children who are at risk of BD [102-105]. Nadkarni and Fristad examined the 
effect of multi-family psycho-educational psychotherapy for 8 weeks on 17 subjects with 
depressive symptoms [102]. A lower conversion rate to BD spectrum disorders was observed 
in the treated group after a 1-year follow-up. In an open study, which was conducted in 13 
children of adults with BD with subthreshold mood symptoms, an improvement in 
symptomatology and functioning levels after a 1-year follow-up was found in youths who 
received Family Focused Therapy for High Risk children (FFT-HR), in addition to their usual 
treatment [103]. FFT-HR was associated with a faster recovery in a controlled randomised 
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trial conducted in 40 subjects over 12 months [104]. Interpersonal and Social Rhythm 
Therapy (IPSRT), which targets altered social and sleep patterns, showed encouraging 
findings in a pilot study conducted on 13 youths [105]. A randomised controlled multi-centre 
clinical trial is being conducted to evaluate the efficacy and safety of a specific cognitive-
behavioural psychotherapy (CBT) for young people who are at risk of BD [106]. 
 
Pharmacotherapy interventions 
Although mood stabilisers and atypical antipsychotic medications exhibit efficacy for the 
curative treatment of manic episodes in adolescents [107,108], their efficacies in the 
treatment of prodromal mood symptoms are largely unknown. Thus far, only four studies 
have been conducted to evaluate their efficacy in this context [109-112]. A study on 30 
youths who suffered from prepubertal major depressive disorder, with putative predictors of 
future BD, was performed to evaluate the efficacy of lithium. In this 6-week, double-blind, 
placebo-controlled trial, lithium was not found to be more efficacious than the placebo. 
However, the effect of lithium on the prevention of the onset of BD was not examined [109]. 
The effect of valproate sodium was evaluated in a 12-week open trial that included 24 
children with first-degree relatives with BD and major depressive disorder, cyclothymic, 
dysthymic, attention-deficit/hyperactivity disorder, or other affective symptoms. Of the 23 
subjects who completed the trial, 18 (78%) were considered to be “very much improved” or 
“much improved” [112]. A randomised, placebo-controlled study was conducted to evaluate 
the efficacy of valproate sodium in 56 youths who had at least one biological parent who 
suffered from BD, BD-NOS, or cyclothymia. After 5 years of follow-up, the treated group 
did not differ from the placebo group with respect to the survival time to the discontinuation 
of medication (the primary study outcome variable) or discontinuation due to a mood event 
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[110]. The effect of quetiapine has been evaluated in a 12-week open trial in 20 adolescents 
with first-degree relatives with BD-NOS, BD-II, dysthymia or major depressive disorder, 
with a response rate of approximately 87% [111]. Different authors have suggested that in the 
early phases, intervention should focus on non-specific neuroprotective strategies and 
psychosocial intervention, while considering the few potential side effects compared to 
lithium or antipsychotics [113,80,114,115]. McNamara et al. recommended that patients with 
prodromal symptoms should be treated using omega-3 fatty acids and vitamins [113]. 
Preclinical and clinical studies supported the positive impact of omega-3 fatty 
supplementation for reducing depressive symptom severity in children and adolescents with 
mood disorder [116]. Favourable effects of omega-3 fatty supplementation were observed in 
the case of bipolar depression, and manic episodes, according to a meta-analysis of five 
clinical trials conducted in BD patients [117]. Patients who fulfil the criteria for BD should be 
treated in accordance with current recommendations for manic or hypomanic episodes.  
 
Limitations and further research 
The scientific evidence that is available with regard to the effects of psychotherapeutic 
interventions is dramatically insufficient for meeting the needs of clinicians. The effect of 
interventions that target environmental risk factors (e.g., substance use) has not been properly 
evaluated on the future risk of developing BD [107,26,18]. The neuroprotective effect of anti-
inflammatory agents must be evaluated on youths who are at risk of BD.  
 
 
3. Staging models to define individual subthresholds for intervention 
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Different staging models 
Given the consequences of a delayed intervention and the importance of long-term 
tolerability, models that are based on a measure of individual risk for developing BD have 
been proposed. Clinical staging models have been proposed as a rational method to classify 
patients according to their level of risk of developing BD [100,118-122,113]. They provide a 
framework that could help to implement a gradual approach for the interventions. For 
example, safe and well-tolerated interventions could be proposed at an early stage, although 
treatments that are more likely to be associated with adverse effects should be reserved for 
those who have a higher risk for transition [123]. Table 2 presents the staging models that 
were proposed for BD and the definition of the stages for each one. It should be noted that 
certain staging models, such as those developed by Berk or Kapczinski, do not specifically 
focus on the transition to BD and instead encompass all of the natural courses of the disease, 
from an early stage without specific symptoms (e.g., stage 0 in Berk’s model) to a severe 
form (e.g., stage 4 in Berk’s model) [124,6,31]. 
 
[Insert Table 2 about here] 
 
Three staging models were specifically developed to focus on the transition from the at-risk 
stage to the onset of a first manic or hypomanic episode [100,120,121]. These models are 
based on specific scales to measure different risk factors (as illustrated in Table 1) and to 
detect psychopathological and functional impairments that precede the onset of BD. Corell et 
al. developed the “Bipolar Prodrome Symptom Scale Prospective” (BPSS-P) by 
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retrospectively questioning child and adolescent patients who had experienced their first 
manic episode [100]. Bechdolf et al. operationalised the category of “Bipolar at Risk” (BAR) 
by analogy to the Ultra-High-Risk criteria for psychosis [119]. Leopold et al. set up the 
“Early Phase Inventory for Bipolar Disorders” (EPIbipolar) which is based on a systematic 
review of the literature that concerns putative risk factors for developing BD in young adults 
[121]. The notions of “subclinical-attenuated” [100], “subthreshold manic symptoms” [119] 
and “subthreshold affective symptoms“ [121] are based on findings from prospective studies 
that were conducted on the general population, in the offspring of patients with BD, in people 
with unipolar depression and in retrospective studies on BD patients. Berk et al. proposed a 
staging model that encompassed all of the natural history of BD, from the early, pre-risk 
status to severe persistent disease [124]. This model focussed more specifically on the distinct 
neurobiological correlates of the stages of the disorder. The description of each stage referred 
to not only the clinical symptoms but also the functional impairments and cognitive 
difficulties. This initial model was further developed by Kapczinski [6]; their work 
emphasised the assessment of patients in the inter-episodic period and included a latent phase 
and four stages.  
 
Validity of staging models 
A staging model should be able to classify patients according to their level of severity and to 
predict a transition to the subsequent stages. Table 3 shows the studies that were conducted to 
measure the validity of the staging models, in particular the predictive value (i.e., the 
possibility of discriminating between different levels of BD) and the reliability (i.e., the 
adequacy of staging between and within the raters).  
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[Insert Table 3 about here] 
 
Corell et al. found a good internal validity and inter-rater reliability of the BPSS-P when 
applied to 205 referred youths [118]. However, no information was available on the 
predictive value of the BPSS-P score. Leopold et al. found 16% of youths to be at risk of BD 
in a referred sample [122]. The measure of the internal consistency of EPIBipolar was not 
reported in the study. Considering the cross-sectional design of the study, the transition rate 
of this group is not known. Bechdolf et al. followed BAR screen-positive individuals (n=35) 
and a matched control (n=35) over a period of 12 months [120]. The clinicians who made the 
diagnoses were blind to the at-risk group allocation. Five cases out of 35 made the transition 
to the first hypomanic/manic episode during the follow-up. The differences between the 
subgroups were not significant. A previous study reported a good inter-rater reliability with 
regard to the Comprehensive Assessment of At-Risk Mental States scale that was used to 
identify the at-risk youths [119]. The distinction between the different groups in the staging 
model proposed by Berk is supported by longitudinal studies, which have stressed the 
progressive increase of residual thymic symptoms, cognitive difficulties and functional 
impairments during the course of the disorder. Reinares et al. used latent class analysis to 
define the subtypes of patients with BD [125]. Two groups were identified; they differed by 
the episode density (the total number of episodes divided by the duration of the illness), level 
of residual depressive symptoms, estimated verbal intelligence and inhibitory control. Such 
findings support the use of both cognitive difficulties and persistent symptoms for assigning 
individual patients into prognostic classes in staging models. Rosa et al. compared the 
functional impairments and cognitive impairments that were presented by 87 referred patients 
according to the levels of the staging models [126]. They found a linear association between 
the severity of the functional impairment and the clinical stages. Moreover, the patients in 
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group III and group IV presented worse cognitive measures than the healthy controls. Further 
studies are needed to measure the transition rate from one stage to the other using 
longitudinal data.  
 
Limitations and further research 
Staging models must be better operationalised and validated by empirical longitudinal 
research. Only one study has examined the predictive value of staging models on longitudinal 
data [120]. Because more focus has been placed on sensitivity, few studies have discussed the 
problems of the specificity of the staging models. Further studies are needed to explore the 
possibility of pluripotent models for serious mental illness [21]; Fusar-Poli suggested that 
focus should be placed on a general at-risk presentation (“Ultra High-Risk”) to prevent both 
psychosis and non-psychosis disorders [71]. Furthermore, the role of biomarkers in 
increasing the predictive value of the staging models, especially at an early stage, deserves 
further investigation.  
 
 
Conclusions 
 
The consideration of minor symptoms as risk factors for the development of complete mental 
disorders and as targets for preventive interventions represents a major paradigm shift in 
psychiatry. The social burden of BD and the poorer prognoses in the case of delayed 
treatment make the development of preventive interventions essential. In this paper, the 
principal limitation for a preventive approach to BD in children and adolescents concerns the 
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lack of specificity of clinical and non-clinical markers. In particular, promising evidence with 
regard to the development of biomarkers exists, but it should be regarded as largely 
preliminary. Despite encouraging results that support the benefits of staging models in BD, 
the algorithms that have been developed still need to be more empirically validated in 
children and adolescents.  
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Table 1. Risk factors for the onset and development of bipolar disorder. 
 
 
 
 
 
 
 
 
 
 
 
Most of the staging models are based on additive risk factors that include genetics, clinical 
phenotypes, personality traits, substance abuse, and environmental factors. 
 
 
 
 
 
First-degree relatives of patients with BD 
Clinical manifestations 
 Subsyndromal bipolar spectrum symptoms 
 Depressive symptoms 
 
Frequent comorbid disorders (anxiety, 
ADHD) 
 Change in sleep 
Temperamental traits 
Substance use 
 Misuse and dependence 
 Antidepressant use 
Environmental factors 
 Abuse and maltreatment 
 Conflictual family 
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Table 2. Staging models developed for bipolar disorder. 
 
Correll et al. 2007, 
2014 [92,110] 
Bipolar Prodrome Symptom Scale 
Prospective 
 
 Early prodromal stages Subclinical, attenuated non-specific manic symptoms 
 Late prodromal stage BD-NOS 
 A subsyndromal stage Cyclothymia and hypomania 
 Syndromal stage BD-I/II 
Bechdolf et al. 2010, 
2014[111,112] 
Bipolar at Risk (BAR) Aged between 15- 25 years 
Fulfil criteria of at least one of three groups within the last 12 months  
Exclusion criteria: history of manic episode ≥ 4 days /psychosis ≥ 7 days; past 
treatment with an antipsychotic ≥ 3 weeks or a mood stabiliser ≥ 6 weeks; IQ 
below the normal range; organic brain disorder. 
 Group 1 Sub-threshold manic symptoms: 
(criteria for a manic episode ≥ 2 consecutive days but < 4 days) 
 Group 2 Depression plus cyclothymic features  
(sub-threshold manic symptoms not meeting group 1 criteria) 
 Group 3 Depression plus genetic risk  
(first degree relative with BD) 
Leopold et al. 2012, 
2014[114,113] 
 
The Early Phase Inventory for Bipolar 
Disorders (EPIbipolar) 
Primary risk factors (1,2) and secondary risk factors (3-7) 
(1) Family history of BD 
(2) Subthreshold affective symptoms 
increasing cyclothymia dynamic 
(hypo)manic prodrome 
(3) Changes in sleep and circadian rhythm  
(4) Substance use 
(5) ADHD symptoms or diagnosis 
(6) Impairment of psychosocial functioning 
(7) Symptoms of affective disorder other than BD or fearfulness/anxiety 
 No risk at present  
 Risk status  
 
Specific changes in sleep and circadian rhythm and at least one of the other 
secondary risk factors 
 
 High risk status  
 
One primary and at least one secondary risk factor 
 Ultra-high risk status  
 
More than one primary risk factor 
McNamara et al. 2010 
[105] 
  
 Stage I Putative risk factors without prodromal symptoms 
First-degree relative 
Physical/sexual abuse 
Psychosocial stress 
Substance use/abuse 
Stimulant; medications 
N-3 fatty acid deficiency 
 Stage II Prodromal clinical features:  
ADHD; unipolar depression; hypomania; anger/irritability; anxiety 
 
 Stage III Onset of an episode of (hypo)mania  
Berk et al. 2014 [116]   
 Stage 0 Increased risk of BD; no specific current symptoms 
 Stage 1a Mild or non-specific symptoms of mood disorder 
 Stage 1b Ultra-high-risk: moderate but subthreshold symptoms, with neurocognitive 
changes and functional decline to caseness  
 Stage 2 First episode of threshold mood disorder 
 Stage 3a Recurrence of sub-threshold mood symptoms 
 Stage 3c Multiple relapses  
 Stage 4 Severe, persistent illness as judged on symptoms, neurocognition and disability 
criteria 
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Kapczinski et al. 
2009; Brietzke et al. 
2012 [6,29] 
  
 Latent stage Individuals at an ultra-high-risk for developing BD present mood and anxiety 
symptoms and increased risk (e.g., positive family history) 
 Stage I Patients who have a diagnosis of BD and return to a baseline level of functioning 
when the episodes resolve (without cognitive impairment) 
 Stage II Mild functional impairment confined to co-morbidities (rapid cycling or current 
axis I or II comorbidities, transient cognitive impairment) 
 Stage III Severe impairment in cognition and global functioning (unable to work or very 
impaired performance) 
 Stage IV Patients are unable to live autonomously due to BD morbidity 
  
  
Table 3. Evaluation of the internal and external validity of staging models developed for bipolar disorder. 
 Methods Population Scales Diagnosis/Classification Internal validity Predictive value 
Correll et al. 
2014 [110] 
 
Cross-
sectional 
study 
 
N=250 
12-23 years 
old 
US 
 BPSS-P All mood spectrum disorders 
n=129 (52%) 
Depression spectrum 
disorders n=77 
Mood disorders NOS n=14 
BD-NOS n=14 
BD-I/BD-II/ Cyclothymia 
n=11 
For General 
symptoms  
α=0.74  
ICC = 0.939 
 
Manic symptoms 
α=0.87  
ICC = 0.934 
 
Depressive 
symptoms 
α=0.89 
ICC = 0.985 
No evaluation 
Leopold et al. 
2014 [114] 
 
Cross-
sectional 
study 
N=180 
12-40 years 
old 
Germany 
EPIbipolar; 
BPSS-P 
At risk n=29 (16%) 
 
No evaluation No evaluation 
Bechdolf et 
al. 2010 
[111] 
 
Retrospective 
study 
medical file 
audit 
follow-up 
265 days 
N=173 
15-24 years 
old 
Australia 
 
Comprehensive 
Assessment of At-
Risk Mental 
States 
 
 
At-risk n=22 (13%) 
 
Classification 
BAR/non-BAR 
k=0.83 
Conversion rate  
22.8% 
OR=44.12  
[4.87-400.10] 
 
Bechdolf et 
al. 2014[112] 
 
 
Prospective 
study follow-
up 12 months 
 
N=559 
15-24 years 
old 
Australia 
Comprehensive 
Assessment of At-
Risk Mental 
States 
 
At risk n=35 (6%) 
Group 1 n=10 
Group 2 n=20 
Group 3 n=3 
Group 1+2 n=2 
Classification 
BAR/non-BAR 
k=0.83 
 
Conversion rate  
14.3% 
Group 1n=3 
Group 2 n=2 
Group 3 n=0 
  
BPSS-P= Bipolar Prodrome Symptom Interview and Scale–Prospective; ICC= intra-class 
correlation; α = Cronbach’s alpha; k = Cohen’s Kappa 
EPIbipolar= Early Phase Inventory for bipolar disorder 
 
 
  
Figure 1. Developmental course of bipolar disorder. 
 
Sympt=symptoms; The high rate of comorbid disorders during childhood, as well as the 
on-going development of emotion regulation skills partly explained the low level of 
specificity of mood symptoms at this age. In contrast, the presentation of mood disorders 
in adolescents is more similar to that described in adults
  
  
 
